{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825894072077952.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.1840060203"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.1840060203"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-198603000-00002"}},{"identifier":{"@type":"NAID","@value":"30026210524"}}],"dc:title":[{"@value":"Clinical, Virologic and Histologic Outcome Following Seroconversion From Hbeag to Anti–Hbe in Chronic Hepatitis Type B"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>Seventy consecutive HBsAg– and HBeAg–positive patients with biopsy–proven chronic hepatitis were followed prospectively with serial determinations of SGPT levels and hepatitis B virus serum markers including HBsAg, HBeAg, anti–HBeand hepatitis B virus DNA. During a period of 1 to 11 years (mean ± S.D.: 5.0 ± 2.3 years), 28 patients remained persistently HBeAg positive, most with continuing biochemical and histologic activity, while 41 cases seroconverted to anti–HBe. One patient became HBeAg and anti–HBe negative. After seroconversion, 87.8% ofthe cases showed sustained normalization of SGPT, and clearance of hepatitis B virus DNA from serum and histologic improvement was documented in 79% of the cases who had a control liver biopsy, while 15.8% developed cirrhosis. In two patients (4.9%), the disease remained active despite seroconversion, and both cases had evidence of continuing hepatitis B virus replication. Finally, reactivation of liver damage and of hepatitis B virus replication was observed in three additional patients (7.3%) who had transiently normalized SGPT after seroconversion. All 70 patients were analyzed for hepatitis delta virus markers, and only two persistently HBeAg–positive cases were found positivefor antibody to hepatitis delta virus in serum, one also having hepatitis delta antigenin the liver. These findings indicate that, in chronic hepatitis type B, termination ofvirus replication is associated in most patients with biochemical and histologic regression of inflammatory activity. After anti–HBe seroconversion has occurred, virusreplication and liver disease may persist or reactivate in a small proportion of patients thus giving origin to the well–recognized group of anti–HBe positive, hepatitis B virus DNA–positive chronic hepatitis type B.</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825894072077958","@type":"Researcher","foaf:name":[{"@value":"Giovanna Fattovich"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894072077957","@type":"Researcher","foaf:name":[{"@value":"Massimo Rugge"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894072077953","@type":"Researcher","foaf:name":[{"@value":"Lucio Brollo"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894072077954","@type":"Researcher","foaf:name":[{"@value":"Patrizia Pontisso"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894072077956","@type":"Researcher","foaf:name":[{"@value":"Franco Noventa"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894072077955","@type":"Researcher","foaf:name":[{"@value":"Maria Guido"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894072077959","@type":"Researcher","foaf:name":[{"@value":"Alfredo Alberti"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302172341568384","@type":"Researcher","foaf:name":[{"@value":"Giuseppe Realdi"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"1986-03","prism:volume":"6","prism:number":"2","prism:startingPage":"167","prism:endingPage":"171"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.1840060203"},{"@id":"https://journals.lww.com/01515467-198603000-00002"}],"createdAt":"2007-03-03","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204788889344","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"Ｂ型肝炎治療の今後の展開"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679885529984","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B virus(HBV) carrier clinic. 10 year's experience in a blood center."},{"@value":"Ｂ型肝炎ウイルス（ＨＢＶ）キャリアクリニック　血液センターにおける１０年間の経験から"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681377614208","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"HBVの自然経過と治療方針について"},{"@language":"en","@value":"Natural course and recommendations of therapy for HBV infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698600008510592","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Special Clinic for Hepatitis B Virus Carriers Detected through Blood Donations"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698600791743616","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Superoxide dismutase and total anti-oxidant levels in various forms of liver diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075378198400","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Drug resistance in antiviral treatment for infections with hepatitis B and C viruses"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550386807424","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Improving outcomes for patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824499818052864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Natural course of portal hemodynamics in patients with chronic liver diseases, evaluated by per-rectal portal scintigraphy with Tc-99m pertechnetate"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105974409187072","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A randomized, double-blind, controlled trial of natural interferon-β therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105974821108608","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"肝炎ウイルスキャリアの基礎と臨床"},{"@language":"en","@value":"Basic and Clinical Aspects of Hepatitis Virus Carriers"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.1840060203"},{"@type":"CIA","@value":"30026210524"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_GYlT5DmXGZ2vVzoKUC4byqufI3g"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_GYlT5DmXGZ2vVzoKUC4byqufI3g"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_GYlT5DmXGZ2vVzoKUC4byqufI3g"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_GYlT5DmXGZ2vVzoKUC4byqufI3g"}]}